<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 313 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page312.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=313">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 313 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 313</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=313"><img src="../thumb/313.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>276 / 2020-04                                                            Anti-Microbials - 18.12
   may contin., prev.of risk of HIV transmiss.not proven, elderly, pts.to   Dosage: Concom.didanosine 2 hrs.aft.Reyataz,  recomm.with concom.warfar., CG monit. recomm. with concom.Ca
   seek med.advice if experienc.joint pain/ aches/stiffn./movem.dif-  Adults: Treatm.-naïve pts: 400 mg once dly.with food. Concom.  chann.block., Reyataz without ritonavir should not be co-admin.
   fic.as osteonecros. poss., incr.bleed.report.in haemophilia type A   ritonavir: 300 mg once dly.with ritonavir 100 mg once dly.with food.   with buprenorphine, alt.non-hormon.contracept.with Reyataz/ ri-
   & B, eff.on activ.of subseq.prot.inhibit.unknown as cross-resist.not   Treatm.-exper.pts: 300 mg once dly.with ritonavir 100 mg once dly.  tonavir combinat.ther.
   fully explor., incr.risk of CV advers. events with concom.salmeterol  with food. Reyataz without ritonavir not recomm.for treatm.-exper.
   Drug interactions: Drugs prim.metabols.by CYP3A may incr.plas-  pts.with prior virolog.fail.  REYDIN, Cipla Medpro
   ma conc., rifampicin & St John’s Wort decr.plasma conc., expos.  Concom.tenofovir: 300 mg & ritonavir 100 mg with tenofovir 300   Lamivudine 300 mg, tenofovir disoproxil fumarate 300 mg, dolute-
   to efavirenz. incr., expos.decr.by saquinavir, expos.incr.by indinavir   mg all as sngl.dly.dos.with food. Reyataz without ritonavir should   gravir sod. 50 mg
   & indinavir expos.incr.by darunavir, bepridil/ lidocaine/quinidine   not be co-admin. with tenofovir.   Indications: Treatm.of HIV infect.adults ≥ 18 yrs.
                                                              (S4) TABS, 52/20.2.8/0451.450
   & amiodarone expos. incr., maraviroc expos.incr., digox.AUC incr.,   Paeds & adolesc.pts: Dos.to be calc.bas.on body weight & should
   poss. decr.warfar.conc., signific.plasma conc.decr.with anticon-  not exceed the recomm. adult dos. Under 6 yrs or &lt;15kg: not   3000532-001: 28, R221,90
                                                              3000532-002: 30, R221,90
   vuls., carbamazepine AUC 12h incr., lumefantrine expos.incr., expos.  recomm. Over 6 yrs: 15 - &lt;20 kg:150 mg; 20 - &lt;40kg: 200mg; ≥
   to Ca chann.block. incr., incr.expos.to clarithromycin/colchicine,   40kg: 300mg. All once dly.with ritonavir 100mg and food. Ritonavir   Dosage: Consult.prod.info.of each therapeut. compon. of regim.bef.
                                                              init.treatm., init.ther.by physic. exper.in HIV infect.managem. Adults:
   dexamethasone decr.expos., fluticasone propion. plasma conc.  oral sol.80-100 mg may be used for paeds. 15 kg-&lt;20 kg who can-  1 tab. once dly. Rifampicin decr.bld lev.of dolutegravir & supplement.
   incr., bosentan propion.plasma conc. incr., HMG-CoA reduct.inhib-  not swall.ritonavir caps./tabs.  dos.of dolutegravir poss.reqd.
   it.plasma conc.marked incr., immunosuppress.expos.incr., steady   Treatm.-naïve paeds.≥ 13 yrs.& ≥ 40 kg unable to tol.ritonavir:   Contraindications: Uncontroll.ren.fail., pregn.& lactat., wom.of
   state syst. expos. to oestrog.bas.contracept.decr., rifabutin expos.  400 mg without ritonavir once dly.with food.  child-bear.age not using high. effect. contracept., concom.adefo-
   incr., sertraline & paroxetine expos. decr., trazodone plasma conc.  Contraindications: Hypersens.to any compon., concom.alfuzosin/  vir dipivoxil/ dofetilide/ pilsicainide/didanosine/metformin, pts. &lt;
   incr., expos.decr.by telaprevir/boceprevir.  rifampicin with Reyataz, concom. quinidine/bepridil & voriconazole
                                with ritonavir & Reyataz, concom.ergot derivat./ cisapride/ St John’s   18 yrs., mod.to sev.liv funct.impairm.
   RETROVIR, GSK [P/S]          Wort/HMG CoA reduct. inhibit/ pimozide/irinotecan, breastfeed.,   Side effects: Freq: Hyperlactataem., headache, insomn., N&V, up-
   Zidovudine.                  sev. hepat.impairm., sev.ren.impairm.manag.with haemodialys.in   per abdom.pain, diarrh., rash, alopec., prurit., arthralg., musc.disord.,
   Indications: Short-term managem.of serious manifestat. of HIV   HIV-treatm.-exper.pts., concom. efavirenz/ indinavir& nevirapine   fatig., malaise, fev., dizzin., flatul., abnorm.dreams, hepatit., incr.liv.
   infects.in pts.unable to take oral zidovudine formulats., to reduc.  not recomm., other protease inhibit.when co-admin.with Reyataz   enzymes., ren.insuffic., incr. creatin., proxim.tubulopathy, ren.fail.,
   matern.-foet.rate of HIV transmiss.  & ritonavir not recomm., concom salmeterol/ fluticasone/other glu-  ac.tubul. necros., nephrogen.diabet.insipid., proteinur. Less freq:
   (S4) IV INFUS, 29/20.2.8/0483.  cocortic.not recomm., oral midazolam/ triazolam, concom.sildenafil   Hypersens., immune reconstit.syndr, lact. acidos./ sev.hepatomeg-
   825018-005: 200 mg/20 ml, 5x20 ml, R518,34  for pulm.arter.hypertens.treatm.  aly with steatos.incl fatal. cases esp.women, lipodystrophy, pan-
   Dosage: Admin.slow IV infus.over 1 hr.; Not for IM inj; Dil.prior to   Side effects: Hyperglycaem.also assoc.with ketoacidos., hyperbili-  creatit., elev. ser. amylase, trans.incr.AST/ALT, neutropen., anaem.,
   admin.accord.to instructs. Adults: 70 kg pt: 1,9 mg/kg every 4 hrs.  rubinaem., report.in combinat. ther.with one or more NRTIs: naus.,   thrombocytopen., rhabdomyolys., decr. bone miner.dens., osteopen.,
   gen. recomm. Low.dos.may be select.depend.on degree of bone   jaund., headache, abdom.pain, lipodystrophy, amnes., somnol.,   fract., allerg.react., sev. ac. exacerbat.of hepatit.B aft.discont. Freq
   marrow reserve but effective.of low.dos.in treatm./prev.of HIV-as-  dizzin., dysgeus., periph. neurolog.sympts., scleral icterus, diarrh.,   unknown: Pure red cell aplas., periph.neuropathy, paraesthes., late
   soc.neurologic.dysfunct.& malign.unknown. Effectiven.of less.freq.  dyspeps., N&V, dry mouth, flatul., gastrit., stomatit.aphth., abdom.   onset neurolog.disord.in childr. expos. in utero, hypophosphataem.,
   dos. remains to be est. Transf.to oral ther.ASAP. Dos. adjustm. poss.  distent., asthen., fatig., allerg.reacts., anx., depress., sleep disords.,   dyspn., abdom. discomf., incr.amylase
   necess.accord.to haematologic. toxic.  insomn., abnorm.dreams, disorientat., hypertens., syncope, oed.,   Warnings and special precautions: Safety & effic. not est.in HBV
   Matern-foet.transmiss.prophylax: Oral treatm. until labour   palpitat., dyspn., pancreatit., hepatit., hepatosplenomeg., rash,   & HIV co-infects., monit. hepat. funct.for sev. mnths. in pts.co-infect.
   commenc. Admin.IV 2 mg/kg bm over 1 hr.follow.by contin.infus.of   alopec.,urticar., eczema, prurit., DRESS syndr., angioed., vasodilat.,   with HIV & HBV who discont.ther.& appropr.init.of anti-hepatit. B
   1 mg/kg/hr until umbilic. cord clamp. Give to new born oral sol.as   vesiculobull. rash, Stev.-Johns.syndr., arthralg., musc.atrophy, my-  ther. poss.necess., eval.for signs of fat redistribut., CV risk assessm.in
   describ. Babies unable to receiv.oral dos.admin. 1,5 mg/kg bm.over   alg., myopathy, haematur., pollakiur., proteinur., kidn. pain, nephro-  pts.with evid.of lipodystrophy, immune reconstitut.inflam.syndr., pts.
   30 mins.every 6 hrs.         lithias., interstit.nephrit., gynaecomast., chest pain, fev., malaise,   to seek med.advice if exper.joint pain/aches/ stiffn./ movem.diffic.
   Contraindications: Abnorm.low neutrophil.cell counts (less than   gait disturb., anorex., incr.appet., decr.weight, weight gain, periph.  as osteonecros.poss., opportunist. infects.& other HIV complic.may
   0,75x10  litre)/Hb levels (less than 7,5 g/decilitre), concom.stavudine  oed., extrem.pain, nas.congest, cough, oropharyng.pain, wheez.,   still devel., ARV ther.will not prev.transmiss.through sex. cont.& bld.
      9
                                           nd
                                            rd
   Side effects: Very comm: Naus. Comm: Anaem., neutropen.,   rhinorrh., asymptomat. 2 /3 -degree AV block, QTc prolongat., tor-  transfus.& appropr.precaut.to contin., discont.in pts.develop. clinic./
   leucopen., hyperlactataem., dizzin., vomit., abdom.pain, diarrh., rais.  sades de pointes, neutrop., elev.CK/ALT/SGPT/AST/ SGOT/ lipase   lab.find. suggest. lact.acidos./hepatotox., pts.with known risk for
   bld.lev.of liv.enz. & bilirub., myalg., malaise. Uncomm: Thrombo-  , diabet.mellit., cholelithias., cholecystit., cholestas.  liv.dis, pts.with hepatomegaly/ hepatit/ other risk facts.for liv.dis./
                                                              hepat.steatos., pts.co-infect. with hepatit. C & treat.with alpha in-
                                Warnings and special precautions: Safety dur. pregn. not est.,
   cytopen., pancytopen., dyspn., flatul., rash, prurit., myopathy, fev.,
   gen.pain, asthen. Rare: Pure red cell aplas., lactic acidos., anorex.,   new onset/exacerb.of exist.diab. mellit., hyperglycaem., diabet.  terferon & ribavarin, eff.on clinic.progress.of HIV-1 not demonstrat.,
                                                              investig.childr.expos.in utero to nucleoside & nucleotide analog.for
                                ketoacidos.occur., CV risk assessm.in pts.with evid.lipodystrophy,
   anx., depress., insomn., paraesthes., somnol., loss of mental acu-
   ity, convuls., cardiomyopathy, cough, oral mucosa pigmentat., taste   mild to mod.hepat.impairm., poss.incr.bleed.by haemophiliacs, im-  poss. mitochondr. dysfunct.in case of relev.S&S, discont. ther.until
                                mune reconstit.syndr.present. with paradoxic.detiorat.of treat.in-
                                                              pancreatit.excl.in cases of N&V/abdom. pain/ elev.biochem.mark.,
   disturb., dyspeps., pancreatit., liv.disords.incl.sev.hepatomegaly with
   steatos., nail & skin pigmentat., urticar., sweat., urin. infreq., gynae-  fect./unmask.of asymptomat. opportunist.dis.occur.within 3 mnths   monit.liv.funct.in pts. with pre-exist.liv.dysfunct., cons.ther.interrupt./
                                of init.ART commonly in pts.with low CD4 counts. resid. opportunist.
                                                              discont.if evid.of worsen.liv.dis., ren.funct. impairm., poss.incr.conc.
   comast., chills, chest pain, influenza-like syndr. Very rare: Aplast.   infects.necessit.furth.eval.& treatm., pts.to report joint ache/pain/  of Reydin &/ other ren. elimin. meds with meds.reduc.ren.funct./
   anaem. Unknown: Redistribut./accumulat.of body fat.  stiffn.& diff. in movem.as osteonecros.poss., opportun.infects./ oth.   compete for act. tubul.secret, monit.ren.funct.bef.init.ther & peri-
   Warnings and special precautions: Concom self-admin. med.,   HIV complicat.may contin.to devel., monit.vir. load/ CD4 counts reg.,   odic.thereaft.,avoid combin.with concurr./ recent nephrotox.meds.,
   limit.data on IV use exceed.2 wks., avoid use dur.first trimest.pregn.  risk of HIV transm.through sex. cont./bld.contaminat.not prevent., PR   avoid in antiretrov. exper.pts. with HIV-1 harbour.K65R mutat., bone
   not est., lactat., teratogenic in anim, limit.data for use in childr., not a   interv. prolongat. potent., pre-exist.conduct.syst.dis., caut. with PR-  monit. in pts. with patholog.bone fract.hist./ osteopen.risk, incr.risk
   cure for HIV, pts.remain at risk of develop.illn.& opportunist.infects.  interv.prolongat.agents (eg atenolol, diltiazem, verapamil), discont.  for sev.hepat.adverse effs. in chron.hepatit.B or C co-infect., ref.to
   assoc.with immune suppress., neoplasm incl.lymphoma develop.risk   if sev.skin rash devel., incr.risk for furth.transamin.elev.in underly.   PI of concom. hepat.B or C meds., limit.data in elderly &gt; 65 yrs., dis-
   unknown,transmiss.still poss.to inft.in pregn. women despite ther.,   hepatit.B/C or mark.transamin.elev., eval.for alternat. etiolog.in pts.  cont.ther.immed.if any hypersens. react. susp./occurs.& init.appropr.
   lact.acidos.& sev. hepatomeg.with steatos., known risk facts.for liv.   with elev.bilirubin with hepat. transamin.elev., no long-term safety   ther., avoid in wom. plan.pregn., pregn. test in women of childbear.
   dis., suspend in case of any find.suggest.of lact. acidos./hepatotoxic.,   data avail. for pts.exper.persist.elev.in bilirub.&gt; 5x ULN, consid. al-  potent. bef.init./periodic.dur.treatm. & when pregn. suspect., lami-
   investig.child.expos.in utero to nucleoside & nucleotide analog.for   tern.antiretrovir.ther.if jaund./scleral icterus assoc. with bilirub.elev.  vudine excret. in breast milk, monit. with concom.co-trimoxazole,
   poss. mitochondr.dysfunct.in case of relev.S&S, consid. pancreatit.   pres.cosmet. concerns, dos.reduct.not recomm.as long-term effic. of   concom.ETR not recomm.unless receiv.concom.ATV + RTV/ LPV +
   if pt.dev. abdom.pain/naus./vomit./ elev. biochemic.mark & discont.  reduc.dos. not est., discont.treatm.if S&S of nephrolithias.devel., lact   RTV or DRV + RTV, admin.2 hrs.bef./6 hrs.aft. polyval. cation-cont.
   until diagnos.of pancreatit.excl., mod.to sev.ren.impairm., safety &   intol., poss.CNS effs. may influence driv./machine operat., caut.with   antacids, admin.2 hrs.bef./ 6 hrs.aft. Ca/Fe supplem.
   effic. not been est.in pts.with signific.underly.liv. disords./dis, also   erect. dysfunct.concom.PDE5 inhibit.& monit.effs.  Interactions: Lamivudine poss.inhib. intracell. phosphorylat. of zal-
   consult prod.lit.of concom. antiviral ther.for hepatit.B/C, monit.liv.  Interactions: Incr.alfuzosin conc.with poss. hypotens., plasma   citabine, trimethoprim incr. lamivudine plasma lev., lamivudine incr.
   funct.in pts. with pre-exist.liv.dysfunct., discont.in case of exacer-  conc.of drugs metabol. by CYP3A4 (e.g.Ca chann.block./HMG CoA   expos.& peak. plasma lev. of zidovudine, conc.of tenofovir/ concom.
   bat. of liv.dis., clin.exam.to eval.for signs of fat redistribut., monit.  reduct. inhibit.& immunosuppress.incr., plasma conc.decr. by other   med incr.with concom.drugs elimin.by glomerul. & act.tubul.secret.,
   ser.lipids & bld.gluc., immune reconstit. syndr., pts.with chron. hep-  drugs that induc CYP3A4 (e.g.rifampicin), drugs.inhibit.CYP3A4   tenofov.ser.conc. incr.by agents decr.ren.funct., C max & AUC of dida-
   atit. B/C treat.with antiretrovir.ther.are at incr. risk for sev. & potent.  incr. plasma conc., eff.on Reyataz/ eff.on co-admin. drug changes   nosine incr., atazanavir incr.tenofovir C max/ AUC/C min., lopinavir/rito-
   fatal hepat.adverse reacts., monit. hepat.funct.for sev.mnths. in pts.  with ritonavir a potent CYP3A4 inhibit., ritonavir incr. expos., poss.  navir incr.tenofovir AUC/ C min., indinavir incr.tenofovir C max, tenofo-
   co-infect.with HIV & HBV who discont.ther, avoid concom.ribavirin,   incr.CV adv.events with salmeterol, nevirapine expos.incr, life-  vir incr. C max of abacavir/indinavir, tenofovir incr. C max/AUC/ Cmin of
   pts. to seek med.advice if exper.joint pain/aches/ stiffn./ movem.dif-  threaten.reacts with quinidine & co-admin. ritonavir/Reyataz ad-  atazanavir, poss.incr.metformin/dofetilide/ pilsicainide plasma conc.
   fic.as osteonecros.poss., opportunist. infects & other HIV complicat.  min., caut. when Reyataz without ritonavir co-admin. with meds.  with dolutegravir., poss. decr.dolutegravir conc.with oxcarbazepine/
   still poss., risk of transmiss.through sex.contact/ bld. contaminat.not   highly depend.on CYP2C8 with narr. therap. indices, myopathy incl.  phenytoin/ phenobarb./carbamazepine/St John’s Wort though no
   reduc., monit.haematolog. parameters incl.haemoglob.lev./neutro-  rhabdomyolys.with HMG CoA reduct. inhibit, proton pump inhibit.  studies, reduc.dolutegravir plasma conc. with etravine/ efavirenz/
   phil counts wkly., long-term effs.of in utero/inft. expos. unknown,   decr. plasma conc., omeprazole dos.exceed.20 mg/ compar. dos.  nevirapine/ rifampicin, incr.dolutegravir plasma conc.with atazana-
   elderly, prolong.treatm.with atovaquone, separate admin. of concom.  of alternat.proton pump inhibit not recomm., plasma conc.decr.by   vir/ atazanavir+ritonavir, decr.dolutegravir conc. with tipranavir + ri-
   clarithromycin by at least 2 hrs., monit.concom.phenytoin bld.lev.,   H2-recept.antagon., caut.when Reyataz without ritonavir co-admin.  tonavir/ ritonavir+ fosamprenavir/ darunavir+ritonavir.
   incr. neutropen.with low vit. B 12 lev.  with meds. highly depend.on CYP2C8 with narr.therap. indices,
   Interactions: Meds.prim.elimin.by hepat.metabol. esp. via   midazolam & triazolam conc.incr., didanosine/ efavirenz/tenofovir   RITOATAZ, Emcure [P/S]
   glucuronidat.may inhib.metabol.of zidovudine, atovaquone   decr.expos.to Reyataz, do not co-admin.efavirenz.to treatm. exper.   Atazanavir sulph. 300 mg, ritonavir 100 mg
   decr.rate of metabol, reduc. absorbt.with concom.clarithromy-  pts., tenofovir conc.incr., saquinavir expos. incr., incr.expos.to other   Indications: In combinat.with other anti-retrovir. agents for
   cin, intracell. phosphorylat.of stavudine inhibit., probenecid   protease inhibit.with Reyataz+ritonavir co-admin., antacids/buffer.   HIV-1 infect
   incr.mean half-life and AUC, rifampicin decr. zidovudine AUC,   meds. reduc.plasma conc., amiodarone/syst. lidocaine & quinidine   (S4) TABS, 48/20.2.8/1247
   lamivudine incr.C max, poss. incr. toxic.risk with potent nephro-  conc.incr., expos.to warfar./ TCA’s incr.with potent.to prod.ser./life   3001247-001: 30, R467,70
   tox./ myelosuppres. meds.    threat. events, trazodone plasma conc.poss.incr., rifabutin expos.incr.,   Dosage: 1 tab.once dly.with food.
                                                              Contraindications: Mod.to sev.hepat.impairm., concom rifampicin/
                                diltiazem/cyclospor./tacrolimus/ sirolimus expos.incr., ser.cortisol
   REYATAZ, Equity [P/S]        conc.decr.with concom. fluticasone & Reyataz & ritonavir combinat.,   St John’s Wort, concom.meds. highly depend.on CYP3A4 for clear.&
   Atazanavir sulph.            plasma conc.of fluticasone incr.with Reyataz alone, clarithromycin   with narrow therap. wind.incl.digoxin/amiodarone/bepridil/ fle-
   Indications: In combinat.with other anti-retrovir. agents for HIV-1   conc.incr.caus.poss. QTc prolongat., conc.of concom.buprenorphine/   cainide/ encainide/propafenone/quinidine/anti-histamines/ ergot
   infect.in childr.≥6 yrs.& adults. Effic.demonstrat. in both antiretrov.  norbuprenorphine incr., atazanavir plasma conc. signif. decr.when   alkaloids/cisapride/pimozide/  triazolam/ midazolam/ketoconazole/
   naïve & treatm. exper. pts.  buprenorphine is co-admin.with Reyataz without ritonavir, ethinyl   itraconazole/ voriconazole/ lovastatin/simvastatin/quinidine, safety
   (S4) CAPS, A39/20.2.8/0088, 0089  estradiol & norethindrone conc.incr., PDE5 inhibit.conc. substant.   in pregn.& lactat./elderly not est.
   708257-001: 150 mg, 60, R275,33  incr., caut.with ketoconazole & itraconazole with Reyataz & ritona-  Side effects: Atazanavir: Freq: Abdom.pain, diarrh., dyspeps.,
   708258-001: 200 mg, 60, R330,40  vir, do not admin. voriconazole with Reyataz & ritonavir, INR monit.   N&V, asthen., fatig., dizzin., headache, insomn., periph.neurolog.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page312.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page308.html">308</a>&nbsp;&nbsp;&nbsp;<a href="page309.html">309</a>&nbsp;&nbsp;&nbsp;<a href="page310.html">310</a>&nbsp;&nbsp;&nbsp;<a href="page311.html">311</a>&nbsp;&nbsp;&nbsp;<a href="page312.html">312</a>&nbsp;&nbsp;&nbsp;<a href="page313.html">313</a>&nbsp;&nbsp;&nbsp;<a href="page314.html">314</a>&nbsp;&nbsp;&nbsp;<a href="page315.html">315</a>&nbsp;&nbsp;&nbsp;<a href="page316.html">316</a>&nbsp;&nbsp;&nbsp;<a href="page317.html">317</a>&nbsp;&nbsp;&nbsp;<a href="page318.html">318</a>
             </td>
             <td width="35%"><a href="page314.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page314.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
